FMR LLC lifted its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 49,000.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,304,114 shares of the company's stock after purchasing an additional 1,301,458 shares during the quarter. FMR LLC owned about 1.91% of Phathom Pharmaceuticals worth $23,578,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in the company. Summit Financial Wealth Advisors LLC bought a new position in shares of Phathom Pharmaceuticals in the third quarter worth $525,000. Eagle Asset Management Inc. increased its holdings in shares of Phathom Pharmaceuticals by 25.9% in the third quarter. Eagle Asset Management Inc. now owns 455,196 shares of the company's stock worth $7,675,000 after purchasing an additional 93,733 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Phathom Pharmaceuticals by 2.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 292,860 shares of the company's stock worth $5,295,000 after purchasing an additional 6,990 shares during the period. Intech Investment Management LLC bought a new position in shares of Phathom Pharmaceuticals in the third quarter worth $207,000. Finally, Jennison Associates LLC increased its holdings in shares of Phathom Pharmaceuticals by 112.7% in the third quarter. Jennison Associates LLC now owns 5,866,389 shares of the company's stock worth $106,064,000 after purchasing an additional 3,108,810 shares during the period. Institutional investors own 99.01% of the company's stock.
Phathom Pharmaceuticals Stock Down 3.9 %
NASDAQ:PHAT traded down $0.36 during midday trading on Tuesday, hitting $8.93. The company had a trading volume of 806,013 shares, compared to its average volume of 911,159. Phathom Pharmaceuticals, Inc. has a 52-week low of $6.07 and a 52-week high of $19.71. The stock's fifty day moving average price is $13.62 and its 200-day moving average price is $13.24. The company has a market capitalization of $610.61 million, a PE ratio of -1.67 and a beta of 0.56.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on PHAT shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $26.00 price target on shares of Phathom Pharmaceuticals in a report on Friday, September 13th. HC Wainwright reiterated a "buy" rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Monday, August 12th.
Get Our Latest Research Report on Phathom Pharmaceuticals
About Phathom Pharmaceuticals
(
Free Report)
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Featured Stories
Before you consider Phathom Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.
While Phathom Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
